Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

efgartigimod alfa

A human immunoglobulin G1 (IgG1)-derived Fc fragment that targets the neonatal Fc receptor (FcRn), with potential FcRn blocking activity. Upon administration, efgartigimod alfa targets, binds to and blocks FcRn, thereby preventing FcRn from recycling IgG back into the systemic circulation. This causes a reduction in IgG blood levels, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis. FcRn binds to IgGs and prevents their lysosomal degradation, thereby extending IgG half-life and increases the availability of pathogenic IgG antibodies that are present in certain severe autoimmune diseases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:efgartigimod alfa-fcab
US brand name:Vyvgart
Code name:ARGX 113
ARGX-113
ARGX113
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search